Imatinib use extended

The licence for Glivec (imatinib) has been extended to include the treatment of adult patients with: - newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia integrated with chemotherapy, or as monotherapy in patients with relapsed or refractory disease. - unresectable dermatofibrosarcoma protuberans or patients with recurrent and/or metastatic disease who are not eligible for surgery.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from MIMS

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

Experts urge vitamin D supplementation and call for research into possible COVID-19 benefits
Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

New rapidly acting insulin launched

New rapidly acting insulin launched

Lyumjev is a new 'ultra rapidly acting' formulation...